Drug Trial Radar · NCT00524862
Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death
Last checked: Nov 20, 2026Latest source record: Jul 31, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5,000
Planned (sponsor's estimate)
Start
Oct 2007
Primary completion
Apr 2011
Study completion Apr 2011
Sponsor
- Lead sponsor
- Unity Health TorontoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long Term Care
- First posted
- Sep 5, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recent ACC/AHA/ESC guidelines recommend prophylactic ICD implantation in most patients with coronary heart disease and LVEF \< 40%. Current Canadian guidelines recommend ICDs for primary prophylaxis in CAD patients with LVEF \< 30% (Class I recommendation). There are very sparse data to recommend ICD implantation in patients with EF between 30 and 40 %. This study will randomize patients with CHD and an EF between 30 and 40% to ICD therapy vs. No ICD therapy. The primary outcome is mortality and the study is powered as a non-inferiority trial to test the hypothesis that mortality in patients with no ICD is not more than 1% greater (absolute yearly increase) than patients receiving an ICD.
Conditions
- Coronary Heart Disease
- Congestive Heart Failure
- Ventricular Dysfunction
- Low Cardiac Output
- Sudden Cardiac Death
Interventions
Optimized medical therapyDrug
Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
Implantable Cardioverter DefibrillatorDevice
an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortalityTime frame: minimum 1 year follow-up (maximum 6 year)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Hamilton Health Sciences - Hamilton General
Hamilton, Ontario, Canada
Kingston General Hospital
Kingston, Ontario, Canada
London Health Sciences - University Campus
London, Ontario, Canada
Trillium Health Centre - Mississauga
Mississauga, Ontario, Canada
Southlake Regional Health Centre
Newmarket, Ontario, Canada
University of Ottawa Heart Institute
Ottawa, Ontario, Canada
Rouge Valley Health System - Centenary
Scarborough Village, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
University Health Network - Toronto General Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.